Vol. 4, Issue 8 (2015)

Author(s):
A Tattis, IA Zupanets, SK Shebeko, IA Otrishko, Ie F Grintsov

Abstract:
In the article was discussed the results of preclinical study of lipid-lowering potential of the drug “Altsinara”, tablets for oral use production of private joint stock company SPC “Borschagovsky CPP”. It was shown that the drug “Altsinara” at the conditions of therapeutic and prophylactic application in rats with tvin hyperlipidemia had an overall positive impact on the course of the experimental pathology. Thus “Altsinara” exhibits a statistically significant hypolipidaemic activity, probably reducing the lipid metabolism such as total cholesterol, cholesterol of LDL, triglycerides and β-lipoproteins in the blood of animals. Lipid-lowering properties of the drug “Altsinara” have antiatherogenic character because relate primarily the atherogenic lipid fractions, such as LDL and β-lipoproteins, resulting in a significant decrease of atherogenic index in rats on the background of the development of hyperlipidemia. By comparison, the results of the study of lipid-lowering properties of the drug “Altsinara” was set the conditionally effective dose – is 100 mg/kg. Thus, the results of the study indicate that “Altsinara” is a perspective remedy of lipid-lowering and anti-atherogenic action.